Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
The paper systematizes data on the pharmacokinetics, molecular and cellular mechanisms of action of chondroprotectors (CPs), by using chondroitin sulfate (CS) and glucosamine (GA) as an example. It presents current ideas about the mechanisms of their absorption and penetration into the joint tissues...
Main Author: | A. S. Dukhanin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/830 |
Similar Items
-
Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
by: A. P. Rebrov, et al.
Published: (2016-06-01) -
Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
by: E. V. Zonova
Published: (2021-04-01) -
The efficacy and tolerability of the slow-acting combined agent glucosamine and chondroitin sulfate in gonarthrosis patients tacking no nonsteroidal anti-inflammatory drugs
by: A. P. Rebrov, et al.
Published: (2016-01-01) -
Basic symptom-modifying delayed-action drugs in therapy of osteoporosis
by: Vladimir Vasil'evich Badokin, et al.
Published: (2011-09-01) -
Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
by: N. V. Chichasova, et al.
Published: (2015-06-01)